Journey Medical Corporation (DERM)
NasdaqCM · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$4.97 (-1.00%) as of
Key statistics
- Market cap
- 140.28M
- Forward P/E
- -82.83
- EPS (TTM)
- -0.2200
- Dividend yield
- 0.00%
- 52-week range
- 4.3100 – 9.5550
- Beta
- 1.11
- Revenue (TTM)
- 68.18M
- Profit margin
- -8.95%
- Analyst target
- $13.75
- Volume
- 118.39k
About Journey Medical Corporation
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Scottsdale, AZ, United States
- Employees
- 58
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.